慢性肾脏病贫血治疗新选择:缺氧诱导因子激活剂综述
本综述聚焦慢性肾脏病贫血治疗中缺氧诱导因子脯氨酰羟化酶抑制剂(HIF-PHI)这类口服新药,阐述其通过激活缺氧诱导因子促进内源性促红细胞生成素生成并改善铁代谢的机制,同时讨论其靶向与非靶向效应及心血管安全性问题,并探讨对临床实践包括肾移植受者的潜在影响。
要点
- HIF-PHI为口服药物,可有效提升并维持CKD患者血红蛋白水平
- 部分国家因未透析CKD患者心血管安全性担忧限制HIF-PHI使用
- 综述讨论HIF-PHI对临床实践的影响及在肾移植受者中的潜在应用
核心结论
- HIF-PHI是治疗CKD贫血的新型口服药物,但部分药物因未透析患者心血管安全性担忧在部分国家使用受限。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- HIF-PHI通过激活缺氧诱导因子刺激内源性促红细胞生成素生成并改善铁代谢。
- HIF-PHI可有效提升并维持CKD患者血红蛋白水平。
- 部分HIF-PHI因未透析CKD患者心血管安全性问题在美国等国仅限维持性透析患者使用。
临床怎么用
- HIF-PHI作为口服贫血治疗选择,需关注其靶向与非靶向效应及心血管安全性。
- 综述探讨HIF-PHI在肾移植受者中的潜在应用。
局限性
- 为综述性文章,未报告系统检索策略及纳入研究的具体特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical challenges and safety concerns associated with the use of erythropoiesis-stimulating agents (ESAs) have provided the rationale for developing novel therapeutic approaches that address the complex pathophysiology of anemia in chronic kidney disease (CKD). Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) are a new class of oral agents that effectively increase and maintain hemoglobin levels in patients with CKD. These agents stimulate the endogenous production of erythropoietin and enhance iron metabolism by activating hypoxia-inducible factors. Despite their efficacy, the use of some HIF-PHIs has been limited to patients on maintenance dialysis in some countries, including the United States, due to unresolved cardiovascular safety concerns in patients with CKD not on dialysis. In this review, we examine the mechanisms of action and erythropoietic effects of HIF-PHIs, evaluate undesirable on-target and off-target effects, and address cardiovascular and other safety concerns that have been raised in comparison to ESAs. We discuss how this novel class of oral anemia drugs may impact clinical practice, including their potential use in kidney transplant recipients.
引用
- Haase VH, Costa NA, Koury MJ, et al. Navigating Anemia Therapy in CKD With Hypoxia-Inducible Factor Activators: A Review. Am J Kidney Dis. 2026. PMID: 41564997. doi:10.1053/j.ajkd.2025.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。